The PD-1 inhibitor pembrolizumab has demonstrated significant efficacy in several tumor types (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s096lbl.pdf). The gene discussed is PDCD1; the disease is neoplasm.